Vaso-occlusion in children with sickle cell disease - Clinical characteristics and biologic correlates

被引:0
|
作者
Dampier, C
Setty, BNY
Eggleston, B
Brodecki, D
O'Neal, P
Stuart, M
机构
[1] St Christophers Hosp Children, Marian Anderson Comprehens Sickle Cell Ctr, Philadelphia, PA 19134 USA
[2] Drexel Univ, Coll Med, Dept Pediat, Philadelphia, PA 19104 USA
[3] Thomas Jefferson Univ, Sch Med, Dept Pediat, Philadelphia, PA 19107 USA
[4] Ctr Comprehens Sickle Cell, Stat & Data Management Ctr, Rho Fed Syst Div, Chapel Hill, NC USA
关键词
sickle cell disease; vaso-occlusion; pain; erythrocyte/endothelial cell adhesion;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Vaso-occlusive pain is a frequent manifestation of sickle cell disease, but most clinical studies have documented only those pain episodes for which patients seek acute care or require hospitalization. Based on limited previous studies, the authors Suggest that pain episodes managed at home are more frequent then those resulting in acute care management but likely share a common pathophysiology. The authors determined the characteristics of vaso-occlusive pain managed at home in 30 subjects (ages 6-19 years) using a self-report diary daily for 6 months. A total of 175 pain episodes were reported in 4,885 days, with 51% lasting 1 day or less. Severe pain, rated as 7 to 10 on a 10-point scale, was reported on 12% of pain days, but most pain was of mild to moderate intensity. A combination of baseline hematologic parameters and biomarkers assessing erythrocyte/endothelial cell adhesion, including hematocrit, fetal hemoglobin, and adhesion ratio, were statistically significant predictors of pain frequency in statistical analyses. Given the overlap in clinical features and predictive hematologic parameters of home-managed and acute care-managed pain, both likely represent a continuum of frequency and severity rather than distinct clinical entities. The higher frequency of these home-managed episodes suggests their potential utility as additional outcome measures in Studies of vaso-occlusive pain.
引用
收藏
页码:785 / 790
页数:6
相关论文
共 50 条
  • [21] Review of an in vitro microfluidic model of sickle cell vaso-occlusion
    Higgins, J. M.
    Eddington, D. T.
    Bhatia, S. N.
    Mahadevan, L.
    TRANSFUSION CLINIQUE ET BIOLOGIQUE, 2008, 15 (1-2) : 12 - 13
  • [22] Differing Definitions of Vaso-Occlusion in Clinical Studies of Sickle Cell Disease Can Result in Differing Outcomes
    Frangoul, Haydar
    Imren, Suzan
    Xuan, Fengjuan
    Li, Nanxin
    Rubin, Jaime
    Hobbs, William
    Locatelli, Franco
    BLOOD, 2023, 142
  • [23] Granulocytic adhesive interactions and their role in sickle cell vaso-occlusion
    Canalli, AA
    Costa, FF
    Saad, STO
    Conran, N
    HEMATOLOGY, 2005, 10 (05) : 419 - 425
  • [24] CIRCULATING PLATELET AGGREGATES IN SICKLE-CELL DISEASE PATIENTS WITH AND WITHOUT VASO-OCCLUSION
    MEHTA, P
    MEHTA, J
    STROKE, 1979, 10 (04) : 464 - 466
  • [25] VASO-OCCLUSION IN SICKLE-CELL DISEASE - PATHO-PHYSIOLOGY OF THE MICROVASCULAR CIRCULATION
    KURANTSINMILLS, J
    KLUG, PP
    LESSIN, LS
    AMERICAN JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 1988, 10 (04): : 357 - 372
  • [26] Targeting ICAM1 to Ameliorate Vaso-Occlusion and Inflammation in Sickle Cell Disease
    Gupta, Parul
    Kumar, Ravindra
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2024, 113 (06) : 730 - 737
  • [27] A rat model for sickle cell-mediated vaso-occlusion in retina
    Lutty, GA
    Phelan, A
    McLeod, DS
    Fabry, ME
    Nagel, RL
    MICROVASCULAR RESEARCH, 1996, 52 (03) : 270 - 280
  • [28] Activated monocytes in sickle cell disease: potential role in the activation of vascular endothelium and vaso-occlusion
    Belcher, JD
    Marker, PH
    Weber, JP
    Hebbel, RP
    Vercellotti, GM
    BLOOD, 2000, 96 (07) : 2451 - 2459
  • [29] Heme oxygenase-1: A potential modulator of inflammation and vaso-occlusion in sickle cell disease
    Belcher, JD
    Welch, TE
    Mahaseth, H
    Sonbol, KM
    Bowlin, PR
    Bischof, JC
    Hebbel, RP
    Vercellotti, GM
    BLOOD, 2004, 104 (11) : 107A - 108A
  • [30] No Evidence for Cell Activation or Vaso-Occlusion with Plerixafor Treatment of Sickle Cell Mice
    Choi, Erika
    Cui, Min-Hui
    Mohandas, Narla
    Yazdanbakhsh, Karina
    Billett, Henny Heisler
    Branch, Craig A.
    Shi, Patricia A.
    BLOOD, 2015, 126 (23)